avacopan ANCA vasculitis
Selected indexed studies
- Avacopan for the Treatment of ANCA-Associated Vasculitis. (N Engl J Med, 2021) [PMID:33596356]
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (Ann Rheum Dis, 2024) [PMID:36927642]
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. (J Am Soc Nephrol, 2017) [PMID:28400446]
_Worker-drafted node — pending editorial review._
Connections
avacopan ANCA vasculitis is a side effect of
Sources
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (2024) pubmed
- Avacopan for the Treatment of ANCA-Associated Vasculitis. (2021) pubmed
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. (2017) pubmed
- Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview. (2024) pubmed
- Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. (2024) pubmed
- Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy. (2025) pubmed
- Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. (2024) pubmed
- ANCA-associated vasculitis-treatment standard. (2024) pubmed
- Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. (2023) pubmed
- Avacopan for ANCA-associated vasculitis - information for prescribers. (2023) pubmed